Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer — Stella

Home/Breast Cancer/

View on ClinicalTrials.gov

Recruiting

Back to Breast Cancer trials

Trial locations(1 site)

China

Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai

Key details

Sponsor

Wenjin Yin

Enrollment target

~229 participants

Started

August 2025

Primary completion

February 2028

Age range

18 Years and older

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.